



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/530,712	11/08/2005	Marc Eloit	270423US0XPCT	9314
22850	7590	03/31/2011		
OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, L.L.P.				
1940 DUKE STREET				
ALEXANDRIA, VA 22314				
EXAMINER				
BURKHART, MICHAEL D				
ART UNIT		PAPER NUMBER		
		1633		
NOTIFICATION DATE	DELIVERY MODE			
03/31/2011	ELECTRONIC			

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com
oblonpat@oblon.com
jgardner@oblon.com

Office Action Summary	Application No. 10/530,712	Applicant(s) ELOIT ET AL.
	Examiner MICHAEL BURKHART	Art Unit 1633

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 30 December 2010.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 22-28,30,31,37-52 and 54-63 is/are pending in the application.
4a) Of the above claim(s) 38-51, 56-60 is/are withdrawn from consideration.
- 5) Claim(s) 22-24,26-28,31 and 61-63 is/are allowed.
- 6) Claim(s) 25, 30, 37, 52, 54 and 55 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) Notice of Informal Patent Application
- 6) Other: _____

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 11/11/2010 has been entered.

Election/Restrictions

Claim 22 is allowable. The restriction requirement, as set forth in the Office action mailed on 11/26/2008, has been reconsidered in view of the allowability of claims to the elected invention pursuant to MPEP § 821.04(a). **The restriction requirement is hereby withdrawn as to any claim that requires all the limitations of an allowable claim.** Claims 25, 30 and 37, directed to adenoviral vectors and methods of making recombinant proteins, are no longer withdrawn from consideration because the claim(s) requires all the limitations of an allowable claim. However, claims 38-51 and 56-60, directed to adenoviral vectors and methods of making a recombinant protein, remain withdrawn from consideration because they do not require all the limitations of an allowable claim.

In view of the above noted withdrawal of the restriction requirement, applicant is advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may

be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application.

Once a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 25, 30 and 37 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 25 recites the limitation "the original replicating adenovirus" in lines 2 -3. There is insufficient antecedent basis for this limitation in the claim.

Further, claim 25 recites that the deletion "comprises all or a part of the region...corresponding to positions 318 and 401 of ESQ. ID NO: 12." Taken with the limitations of claim 22, from which it depends, this introduces confusion as to whether an additional deletion is required, or that the deletion recited in claim 22 "comprises", i.e. contains, some of the DNA sequence found within positions 318 - 401. It would be remedial to word this claim as found in claim 26 if applicants are intending to claim additional deleted sequences.

Claim 30 recites the limitation "said unmodified replicating adenovirus" in lines 1 - 2.

There is insufficient antecedent basis for this limitation in the claim.

Claim 37 recites a method for making a recombinant protein using the vector of claim 22 by expression from a nucleic acid of said vector. However, claim 22 is devoid of any such nucleic acid encoding a recombinant protein. It is thus unclear and confusing what is to be considered a "recombinant" protein in this instance. It would be remedial to amend the claims along the lines of claim 61, for instance.

Claim Objections

Claim 30 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Claim 22 recites "A recombinant canine type 2 adenovirus." However, as best understood, claim 30 seeks to remove this limitation.

Claims 52, 54 and 55 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Claim 52, in part b), recites a "fragment" of the vector recited in claim 22 accompanied by arbitrary up- or downstream sequences. Thus, the claim requires less structure, i.e. nucleotide sequence, than the vector of claim 22.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 52, 54 and 55 are rejected under 35 U.S.C. 102(b) as being taught by Soudais et al (2001, of record). **This rejection is maintained for reasons made of record in the Office**

Action dated 11/16/2009, 6/11/2010, and for reasons set forth below.

Response to Arguments

Applicant's arguments filed 11/11/2010 have been fully considered but they are not persuasive. Applicants essentially assert that Soudais et al do not teach the vector as recited in claim 22. The Examiner agrees, however, claim 52 part b) (claimed in the alternative with part a) does not require the vector of claim 22, only a "fragment" of the vector of claim 22 along with other arbitrary fragments located up- or downstream of the deleted portion. There is no limiting definition of a nucleic acid "fragment" in the specification, and thus it can be as small as one nucleotide chosen arbitrarily from the vector of claim 22. Furthermore, there are no limitations placed on the additional sequences other than they be of a certain size and located up- or downstream.

Conclusion

Claims 22-24, 26-28, 31, 61-63 are allowed.

Art Unit: 1633

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL BURKHART whose telephone number is (571)272-2915. The examiner can normally be reached on M-F 8AM-5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach can be reached on (571) 272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael Burkhart/
Primary Examiner, Art Unit 1633